Conio Massimo, Repici Alessandro, Battaglia Giorgio, De Pretis Giovanni, Ghezzo Luigi, Bittinger Max, Messmann Helmut, Demarquay Jean-François, Blanchi Sabrina, Togni Michele, Conigliaro Rita, Filiberti Rosangela
Department of Gastroenterology, Sanremo Hospital, Sanremo, Italy.
Am J Gastroenterol. 2007 Dec;102(12):2667-77. doi: 10.1111/j.1572-0241.2007.01565.x.
Self-expanding metal stents (SEMS) provide effective palliation in patients with malignant dysphagia, although severe complications and mortality may result. We performed a prospective controlled trial to compare a new self-expanding polyester mesh stent (Polyflex) with SEMS (Ultraflex).
One hundred one patients with unresectable esophageal carcinoma were randomized to placement of a Polyflex (N=47) or a partially covered Ultraflex (N=54) stent. Patients with esophagogastric junction (EGJ) malignancy were excluded.
Placement was successful in 46 (98%) patients with the Polyflex and 54 (100%) patients with the Ultraflex stent. In one patient, the Polyflex stent could not be placed. After 1 wk, dysphagia was improved by at least 1 grade in 100% of the Polyflex group and in 94% of the Ultraflex group. Major complications were observed in 48% of the Polyflex group and 33% of the Ultraflex group. Intraprocedural perforation occurred in 1 Polyflex and 1 Ultraflex patient. Two Polyflex patients had postprocedural hemorrhage. Twenty (44%) patients with a Polyflex stent and 18 (33%) with an Ultraflex stent had recurrent dysphagia because of tumor overgrowth, stent migration, hyperplastic granulomatous reaction, or food bolus impaction. Multivariate analysis showed a significantly higher complication rate with Polyflex than with Ultraflex stents (odds ratio 2.3, 95% CI 1.2-4.4). However, median survival was 134 days with Polyflex and 122 days with Ultraflex stents (P=NS).
No difference was seen in palliation of dysphagia between the two stents. Significantly more complications, especially late stent migration, were observed in the Polyflex group.
自膨式金属支架(SEMS)可为恶性吞咽困难患者提供有效的姑息治疗,尽管可能会导致严重并发症和死亡。我们进行了一项前瞻性对照试验,比较新型自膨式聚酯网片支架(Polyflex)与SEMS(Ultraflex)。
101例无法切除的食管癌患者被随机分为置入Polyflex支架组(N = 47)或部分覆膜Ultraflex支架组(N = 54)。排除食管胃交界(EGJ)恶性肿瘤患者。
Polyflex支架组46例(98%)患者和Ultraflex支架组54例(100%)患者支架置入成功。1例患者无法置入Polyflex支架。1周后,Polyflex组100%的患者和Ultraflex组94%的患者吞咽困难改善至少1级。Polyflex组48%的患者和Ultraflex组33%的患者出现主要并发症。1例Polyflex患者和1例Ultraflex患者在操作过程中发生穿孔。2例Polyflex患者术后出血。20例(44%)置入Polyflex支架的患者和18例(33%)置入Ultraflex支架的患者因肿瘤过度生长、支架移位、增生性肉芽肿反应或食物团块嵌塞出现复发性吞咽困难。多变量分析显示,Polyflex支架的并发症发生率显著高于Ultraflex支架(优势比2.3,95%可信区间1.2 - 4.4)。然而,Polyflex支架组的中位生存期为134天,Ultraflex支架组为122天(P =无显著性差异)。
两种支架在缓解吞咽困难方面无差异。Polyflex组观察到的并发症明显更多,尤其是晚期支架移位。